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Abstract:
Objective: Multiple myeloma is a common haematological malignancy and immune dysfunction is the hallmark of the disease. 
It leads to an increased infection risk, which is still a major cause of mortality. The infection spectrum and characteristics have 
evolved with the introduction of novel agents. An understanding of risk factors that increase susceptibility to infections is 
critical in fighting them. This retrospective investigation aimed to establish the incidence and main characteristics of infections 
in non-transplanted hospitalised myeloma patients in our department over a 3-year period, as well as factors associated with 
infections.  
Materials and Methods: A total of 240 hospitalised patients with multiple myeloma (120 males and 120 females; average 
age: 69 years, range: 41-89 years) who were diagnosed or treated in our department from January 2008 to December 2010 
were included in this study and their data were retrospectively analysed.
Results: Infections were identified in 17.9% of hospitalised patients. The most common pathogen found was Pseudomonas 
aeruginosa. The frequency of gram-positive and gram-negative pathogens was similar. In 37.2% of cases, the agent was not 
isolated. The most common sites of infections were the urinary system and the blood (septicemia). The frequency of infection 
increased with duration of disease and the rate of reinfection was 41.9%. The patients treated with bortezomib had the highest 
infection occurrence. Fatal outcome occurred in 9.3% of cases. 
Conclusion: The factors associated with infections in this investigation were female sex, 3B clinical stage of disease, increased 
serum creatinine and ferritin levels, neutropenia, poor general condition, and presence of catheters. Myeloma patients with 
one or more of these mentioned risk factors should be monitored with particular care in order to decrease the incidence and 
severity of infective complications.
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Introduction 
Multiple myeloma (MM) is a common haematological 
malignancy, and immune dysfunction is one of the hallmarks 
of the disease. The disease-related immunological defects, 
as well as therapy-related immunosuppression, lead to the 
increased risk of infective complications, which are a major 
cause of mortality. 
Malignant plasma cells produce monoclonal paraprotein, 
which is non-functional and crowds out the polyclonal 
immunoglobulins. Hypogammaglobulinaemia, which is 
related to suppression of CD19+ B lymphocytes, exists in a 
great majority of patients with the active disease [1]. Besides 
hypogammaglobulinaemia, numerous immunological 
abnormalities have been observed, such as several defects 
of T lymphocytes, dendritic cells, natural killer cells, 
and the complement cascade [2,3,4,5,6,7]. Quantitative 
and qualitative disorders of neutrophils are related to 
myelosuppressive therapy or bone marrow infiltration [8,9]. 
Furthermore, several other risk factors increase susceptibility 
to infections in MM, such as renal failure, smoking, using of 
various catheters, vertebral collapse, iron overload, or use of 
opiate drugs [10,11].
The spectrum and characteristics of infective complications 
in myeloma patients have evolved with the introduction of 
autologous and allogeneic hematopoietic stem cell transplant 
(HSCT) or different novel drugs, which together cause 
an increasing susceptibility to fungal and viral infections 
[12,13,14,15]. 
The present study has analysed the frequency and 
characteristics of infective complications, as well as factors 
related to risk for infections, in the myeloma patients treated 
at our institution over a 3-year period. 
Materials and Methods 
Retrospectively, using hospital medical documentation, 
240 cases of hospitalised patients with MM (120 males and 
120 females; average age of 69, range of 41-89 years) who were 
diagnosed or treated in our department from January 2008 
to December 2010 were processed. Because the majority of 
patients were hospitalised more than once, the total number 
of our cases was larger than the number of patients included 
in this study (37 males and 35 females, respectively). Only 
patients who were not treated at the time of this study with 
high-dosage therapy and HSCT were included. The diagnosis 
was established according to International Myeloma Working 
Group criteria [16]. The great majority of patients in this 
study had IgG, IgA, or a light chain myeloma; however, 1 
patient with IgD and 1 patient with nonsecretory myeloma 
were also included. Our patients were treated fairly uniformly. 
VAD (vincristine, doxorubicin, and dexamethasone) and MP 
(oral melphalan and prednisone) regimens were mostly used 
as the induction therapy (according to the patient’s age and 
eligibility for high-dose therapy), with thalidomide-based 
protocols as second-line therapy and bortezomib-based 
protocols as third- or next-line therapy. Monotherapy with 
dexamethasone was used as a front-line therapy, as well as for 
postinduction protocol in some patients.
Özet:
Amaç: Multipl miyelom, sık görülen bir hematolojik malignite olup, bağışıklık sistemi disfonksiyonu bu hastalığın en belirgin 
özelliğidir. Bu hastalığın sebep olduğu ileri düzeyde enfeksiyon riski hala başlıca ölüm sebebidir. Enfeksiyonun spektrumu 
ve özellikleri, yeni geliştirilen ajanlarla birlikte değişiklik göstermektedir. Enfeksiyonlara hassasiyeti arttıran risk faktörlerinin 
anlaşılması, bu enfeksiyonlara karşı savaşmak için son derece önemlidir. Bu retrospektif çalışma neticesinde 3 yıldır 
departmanımızda yatırılarak tedavi gören ve transplantasyon yapılmamış miyelom hastalarımızda görülen enfeksiyonların temel 
özelliklerinin saptanması amaçlanmıştır.
Gereç ve Yöntemler: Ocak 2008 ile Aralık 2010 tarihleri arasında departmanımızda tanısı konmuş ve tedavi görmüş toplam 
240 multipl miyelom hastası (120 erkek ve 120 kadın; ortalama yaş: 69, yaş aralığı: 41-89) bu çalışmaya dahil edilmiştir ve bu 
hastalardan elde edilen veriler retrospektif olarak incelenmiştir.   
Bulgular: Hastanemizde yatan hastaların %17,9’unda enfeksiyona rastlandı. En sık görülen patojenin Pseudomonas aeruginosa 
olduğu saptandı. Gram pozitif ve gram negatif patojenlerin sıklığı aynıydı. Olguların %37,2’sinde ajan izole edilemedi. Enfeksiyon 
kaynağının sıklıkla üriner sistem ve kan olduğu görüldü. Hastalık süresince enfeksiyon oranının arttığı ve reenfeksiyon sıklığının % 
41,9 olduğu tespit edildi. En sık enfeksiyon bortezomib ile tedavi edilen hastalarda görüldü. Olguların %9,3’ü ölümle sonuçlandı.
Sonuç: Bu çalışmada enfeksiyonlarla ilişkilendirilen faktörler kadın cinsiyet, ileri evre (III 3B) hastalık, artmış serum kreatinin ve 
ferritin düzeyi, nötropeni, genel durumun bozukluğu ve kateterlerin varlığıydı. Bahsi geçen bu faktörlerden bir ya da ikisine sahip 
miyelom hastalarda görülebilecek enfektif komplikasyon oranını ve şiddetini düşürmek amacıyla hastaların özenli ve dikkatli bir 
bakımla izlenmesi gerekmektedir.
Anahtar Sözcükler: Multipl miyelom, Enfeksiyonlar, Risk faktörleri, Tedavi
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The study was approved by the Medical School of Rijeka 
Ethics Committee. 
The criteria for infection used in our study were increased 
body temperature above the normal range (37 °C) or isolation 
of a microbial agent in patients who also had concomitant 
clinical symptoms and/or humoral signs of infections 
(leukocytosis, neutrophilia, marked “left shift”, or increased 
C reactive protein in comparison with a baseline value). 
The frequency and the basic characteristics of the 
identified infections, such as type of isolated microbial agents, 
site of infection, time of occurrence and outcome of infection, 
rate of re-infections, and type of antitumor therapy at the 
time of infection, were also determined. The factors that 
could influence the pathogenesis and incidence of infections, 
including sex, WHO/ECOG performance status [17], Durie-
Salmon stage of disease [18], International Staging System 
(ISS) score [19], serum creatinine level, immuneparesis 
defined qualitatively (decreased serum concentration of any 
polyclonal immunoglobulin class), neutropenia (defined as 
blood neutrophil count of ≤2x109/L), serum ferritin level, 
and presence of any catheters, were compared and statistically 
analysed in cases with and without infections [17,18,19]. All 
these parameters according to the occurrence of infections are 
listed in Table 1. 
Statistical Analysis 
Data were expressed as means ± standard deviations, 
with the sample size (n). Nominal and ordinal variables were 
analysed with the chi-square test. Normality of distribution of 
continuous variables was tested by the Kolmogorov-Smirnov 
test. For continuous variables with distribution significantly 
different from the norm, we used the median and interquartile 
range, and the differences between the groups for these 
variables were tested with the Kruskal-Wallis test and Mann-
Whitney U test. In the symmetric distribution of continuous 
variables, to display the mean values and dispersion measures, 
we used the arithmetic mean and standard deviation, and their 
comparison was done with Student’s t-test. SPSS for Windows 
(version 17.0, SPSS Inc., Chicago, IL, USA) and Apache 
OpenOffice (version 3.3.0, The Apache Software Foundation, 
Wilmington, DE, USA) were used for statistical analyses. 
The values were considered statistically significant at p<0.05 
(2-tailed). 
Results
Infections were identified in 43 out of 240 (17.9%) 
hospitalised patients. In 27 (62.8%) cases of infection, the 
microbial agent was identified, while in 16 (37.2%) cases, no 
isolation was possible. The most common pathogen found 
was Pseudomonas aeruginosa. The frequency of gram-positive 
and gram-negative bacteria was almost the same. In 10 out of 
27 cases, more than 1 microorganism was isolated (in 9 cases 
2 and in 1 case 3 agents were isolated at the same time). In 
all cases, the identified microorganisms were bacteria, without 
any proven viral or fungal isolates. The frequencies of isolated 
agents are shown in Table 2. 
The most common sites of infections were the urinary 
system in 16 cases (37.2%) and the blood in 7 cases (16.3%). In 
4 cases more than 1 site of infection was found (urinary system 
and blood, as well as upper respiratory tract and blood, both 
in 2 cases). In 8/43 cases (18.6%), the site of infection was not 
identified. The determined sites of infection are summarised 
in Table 3. The average age in the group of patients with 
infections was 69 years and in those without infections was 65 
years, which did not reach statistical significance (p=0.094).
The average disease duration in the cases without infection 
was 17.7 months and in the cases with infection was 33.6 
months, which was statistically significant (p=0.004). 
In 18 of 43 cases, infections occurred in patients who had 
previously suffered from infective complication, which means 
that the re-infection rate was 41.9%. Fatal outcome related to 
infection occurred in 4/43 cases (9.3%).
According to the type of therapy, the highest frequency 
of infections occurred in the group treated with bortezomib 
(14/28) and the lowest with VAD protocol (5/76), as can be 
seen in Table 4. 
Our results established that the factors associated with 
more frequent infections were female sex (p=0.001), poor 
general condition (p<0.001), IIIB 3B (advanced) Durie-
Salmon stage of disease (p=0.007), increased serum creatinine 
(p=0.036), neutropenia (p=0.009), high serum ferritin level 
(p=0.001), and the presence of catheters, especially urinary 
(p<0.001). There was no difference in infection occurrence 
related to the patient’s age (p=0.072), ISS score (p=0.532), or 
presence of immuneparesis (p=0.278).
Discussion
To date, there have been scant data regarding the incidence 
and characteristics of infections in hospitalised myeloma 
patients, especially those who were not treated with high-
dose therapy and HSCT. According to our results, infections 
occurred in 17.9% cases of myeloma patients hospitalised in 
our ward during a 3-year period. The most frequently isolated 
bacteria were Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus epidermidis, and Enterococcus faecalis, and the 
numbers of gram-positive and gram-negative infections were 
almost equal, which is in concordance with the existing data 
[10,20]. These agents caused mainly urinary tract infections 
and bacteraemia. Contrary to recent reports that showed an 
increased incidence of fungal infections [12,13,14,15], none of 
these pathogens or fungal surrogate markers were detected in 
Valković T, et al: Infections in Patients with Multiple Myeloma
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Table 1. Characteristics of tested parameters.
Tested Parameters
Number 
of Cases
Group without 
Infections
Group with 
Infections
Sex
 Male
Female
120
120
111
86
9
34
ECOG
performance
status
0
1
2
3
4
16
88
70
45
20
16
85
60
30
5
0
3
10
15
15
Durie-Salmon
stage of
disease
1A
2A
2B
3A
3B
6
51
1
106
59
5
47
0
89
40
1
4
1
17
19
International Staging 
System score
1
2
3
54
57
98
44
50
81
10
7
17
Serum creatinine level
≤100 mmol/L (f); ≤120 mmol/L (m) (normal value)
>100≤175 mmol/L (f); >120≤175 mmol/L (m)
>175 mmol/l (f, m)
133
52
49
117
41
35
16
11
14
Immuneparesis Yes
No
No
184
46
160
148
40
138
36
6
22
Neutropenia 1.01-2x109/L
0.51-1x109/L
<0.5x109/L
55
14
3
44
8
1
11
6
2
Serum ferritin level
≤120 μg/L (f);
≤300 μg/L (m)
51 46 5
>120≤240 μg/L (f);
 > 300≤600 μg/L (m)
19 16 3
>240 μg/L (f);
>600 μg/L (m)
32 18 14
Types of therapy
Without therapy
VAD
MP
Thalidomide-based
Dexamethasone
Bortezomib-based
Others
39
76
13
20
55
28
5
32
71
11
17
48
14
1
7
5
2
3
7
14
4
Presence of any 
catheters
Without catheters
UC
CVC
UC, CVC, ITC
CVC, ITC
UC, CVC
190
32
2
2
1
8
179
22
2
0
1
0
11
10
0
2
0
8
 
f: Female, m: male; VAD: vincristine, doxorubicin, dexamethasone, MP: oral melphalan and prednisone, UC: urinary catheter, CVC: central venous catheter,  
ITC: intrathoracic catheter.
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cases when fungal infection was part of a differential diagnosis 
[12,13,14,15]. This conflicting finding can be explained by the 
fact that our patients were not treated with high-dose therapy 
at the time of this study. Because of that, prolonged and severe 
neutropenia and mucositis, which are well-known risk factors 
for invasive fungal infections, occurred rarely in our group.
Traditionally, the frequency of infections is the highest 
during the first few months of induction therapy and in the 
later course of advanced disease [9,20,21,22,23,24,25,26]. On 
the contrary, patients who respond to therapy and those in 
the “plateau” phase are at low risk [24]. In our sample, the 
average disease duration in the cases without infections was 
significantly shorter than in the cases with infections, which 
implies that infections tend to occur in the later stage of 
relapsed or refractory disease. This result supports the idea that 
uncontrolled and long-lasting myeloma increases cumulative 
immunosuppression and represents an important infection 
risk factor. Moreover, these patients more often suffer from 
renal failure, neutropenia, bone fractures, neuropathy, and 
other established infection promoters. Our results suggest that 
these subsets of patients are also candidates for antimicrobial 
prophylaxis, just as the patients during the first months of 
induction therapy, which has been proposed by some other 
researchers [27,28].
The data regarding the mortality rate in myeloma patients 
who contract infective complications are quite limited. 
Considering the fact that a significant number of our patients 
suffered from progressive disease, poor performance status, 
and high incidence of bacteraemia, the mortality rate of 9.3% 
seems acceptable.
Anderson et al. reported a significant proportion of 
infections after the VAD regimen, which was probably related 
to dexamethasone-induced T-cell immunodeficiency [29]. 
Thalidomide is not heavily myelotoxic and the infection risk 
is not too high when it is used. However, the incidences of 
infections and pneumonia are higher in MPT than in MP groups 
of patients in some (but not all) clinical studies, which can 
be related to the immunomodulatory functions and indirect 
effects on deep vein thrombosis and peripheral neuropathy 
[30,31,32,33,34,35]. Bortezomib is also not significantly 
myelotoxic, but it mediates potent immunosuppressive effects 
on T cells, strongly connected with herpes zoster infection 
and other infections [36,37,38,39,40,41]. The infection rate 
in patients treated with bortezomib is variable, but Mateos 
et al. reported that 75% of patients treated with melphalan, 
prednisone, and bortezomib had at least 1 episode of infection 
during treatment [42]. According to our results, patients 
Valković T, et al: Infections in Patients with Multiple Myeloma
Table 4. Frequency of infections based on type of 
antitumor therapy.
Types of Antitumor
Therapy
Frequency of
Infections
VAD 6.6% (5/76)
MP 15.4% (2/13)
DEXA 12.7% (7/55)
Thalidomide-based therapy 15% (3/20)
Bortezomib-based therapy 50% (14/28)
VAD: Vincristine, doxorubicin, dexamethasone, MP: oral melphalan and predni
sone, DEXA: dexamethasone.
Table 2. The frequencies of isolated agents.
Isolated
Agent
Number of
Cases
Pseudomonas aeruginosa 9
Escherichia coli 6
Enterococcus faecalis 5
Staphylococcus epidermidis 5
Proteus mirabilis 3
Streptococcus sp. 2
MRSA 2
Staphylococcus aureus 2
Streptococcus pneumoniae 1
Acinetobacter 1
Enterobacter 1
Clostridium difficile 1
Table 3. The determined sites of infection.
Sites of Infection Number of Cases
Urinary tract 16 (37.2%)
Fever of unknown origin 8 (18.6)
Blood (sepsis) 7 (16.3%)
Lower respiratory tract 3 (6.9%)
Gastrointestinal tract 2 (4.6%)
Skin 2 (4.6%)
Sepsis and urine 2 (4.6%)
Sepsis and upper respiratory tract 2 (4.6%)
Upper respiratory tract 1 (2.3%)
Total 43 (100%)
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treated with the VAD regimen had the lowest infection 
incidence (6.6%), but, as already mentioned, VAD was used 
as the first-line therapy. The frequency of infections was 
higher with dexamethasone-monotherapy (12.7%) and 
thalidomide-based protocols (15%), both commonly used as 
second-line therapies. The highest rate of infections was in 
the “bortezomib-based protocols” group (50%). As explained 
above, bortezomib-based protocols were used in this study 
as salvage treatment for refractory/progressive disease in 
patients with severe cumulative malfunction of the immune 
system, which is thought to be the main reason for the highest 
infection rate in patients treated with bortezomib. On the other 
hand, no herpes zoster infection was noticed in our group at 
the time of study, probably because of the prophylactic use of 
acyclovir. 
Among our cases, almost 80% of all infective complications 
were restricted to the female sex, which is quite an interesting 
result. On the other hand, some authors found a higher 
infection rate among men [24,43]. Hargreaves et al. suggested 
that cigarette smoking, which was more typical for men, was 
one of the possible explanations for this [24]. The reasons 
for more frequent infections in women, especially possible 
differences in the infection sites, and urinary catheter 
application among women and men should be analysed in a 
future study on a representative number of patients.   
In our patients, the highest infection rate was observed in 
those with poor performance status, i.e. WHO/ECOG Groups 
3 and 4. This finding was expected because this group of 
patients very frequently had other infection risk factors such 
as advanced age, progressive/uncontrolled disease, renal 
dysfunction, or different catheters.
No difference in infection rate was found between different 
ISS groups of patients, but advanced Durie-Salmon Stage IIIB 
3B was significantly associated with more frequent infective 
complications. Contrary to some other studies [43,44], this 
result supports the idea that large tumour burden, especially 
when associated with renal failure, is an important infection 
risk factor in myeloma patients [43,44]. Like in other 
groups, a positive correlation between renal dysfunction and 
infections was found and these patients had a significantly 
higher rate of infective complications [10,43,45,46,47,48,49], 
which should be included in the estimation of infection risk 
[10,43,45,46,47,48,49].
In contradiction to other studies [10,43,45,46,47,48], the 
prognostic importance of serum polyclonal immunoglobulin 
deficiency as a risk factor for infection was not confirmed in 
our sample [10,43,45,46,47,48]. However, the present study 
evaluated immuneparesis only qualitatively, not quantitatively, 
and the number of patients without immuneparesis was low, 
which could have influenced and limited our results.
Our data confirmed the well-established fact that the 
degree of neutropenia in haematological diseases is related to 
the risk of infections [50,51]. The majority of our cases had 
no neutropenia. However, patients with neutrophil counts 
of less than 1x109/L had a higher infection rate. A previous 
randomised trial showed some benefits for severely neutropenic 
myeloma patients after HSCT treated with granulocyte colony-
stimulating factor (G-CSF) [52]. Although the prophylactic 
use of G-CSF in neutropenic myeloma patients is supported 
on an everyday basis, the question of whether prophylactic use 
or addition of G-CSF to broad-spectrum antibiotics in non-
transplanted myeloma patients really improved their outcome 
is still open and requires new clinical trials.    
This study has shown that patients with high serum ferritin, 
and especially those with levels twice the norm (caused by an 
underlying disease, their treatment, blood transfusions, or the 
infection itself), had a greater infection incidence, which some 
authors have already suggested, particularly in patients treated 
with high-dose therapy [11,53]. This suggests that iron overload, 
and especially free iron, can cause immunosuppression, 
probably due to the damaging of polymorphonuclear and 
macrophage function, T cell development, and facilitation of 
the growth of microorganisms [54].
Indwelling central venous and urinary catheters are 
important devices in haematological disease management but 
catheter-bearing patients have impaired mucosal integrity and 
are at significant risk of infection complications [55,56,57]. 
In our group, patients with different catheters, especially 
urinary, had an increased infection rate in comparison to 
those without catheters. This result highlights the importance 
of our decisions and estimations of possible risk and benefit 
regarding the implantation of different catheters. The rate 
of re-infections among our patients was rather high, which 
implies that a previous infection represents another infection 
risk factor.
Over the last decades we have witnessed remarkable progress 
in the treatment of MM, which resulted in the prolongation of 
survival rates. However, these accomplishments have not been 
achieved only because of transplant procedures and potent 
novel drugs, but also because of better supportive therapy 
including anti-infective drugs.   
According to our results, female sex, advanced clinical 
stage and WHO/ECOG performance status, neutropenia, 
increased levels of serum creatinine and ferritin, presence 
of catheters (especially urinary), and previous infections 
represent infection risk factors in patients with MM. Each 
myeloma patient, especially those with one or more of the 
mentioned risk factors, should be carefully and individually 
studied in order to decrease the incidence and severity of 
infective complications using different approaches.
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